EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes

Francesco Giorgino, Sherwin D'Souza, Lisa Ludwig, Arihiro Kiyosue, Hilda Ibriga, Hyungmin Rha, Max Denning, Wen-Shuo Wu, Laura Fernández Landó, Janet Tobian

JAMA · 2026

DOI: 10.1001/jama.2026.9512 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2026. Verfasst von Francesco Giorgino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative and Precision Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, Un…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Insulin Glargine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effects of orforglipron, an oral, nonpeptide glucagon-like peptide 1 receptor agonist, added to insulin glargine for treatment of type 2 diabetes have not been described.

Objective

To assess efficacy and safety of orforglipron added to titrated insulin glargine in adults with type 2 diabetes and inadequate glycemic control. Design, Setting, and Participants Randomized, double-blind, phase 3 study conducted at 72 sites across the US, Brazil, China, Japan, and Romania between November 10, 2023, and September 15, 2025, in adults with type 2 diabetes taking insulin glargine with or without metformin and/or sodium-glucose cotransporter 2 inhibitors over 40 weeks.

Interventions

Participants were randomized (1:1:1:1) to receive once-daily 3-mg (n = 137), 12-mg (n = 132), or 36-mg (n = 136) dosages of orforglipron or placebo (n = 141), in addition to titrated insulin glargine. Main Outcomes and Measures The primary outcome was mean hemoglobin A 1c (HbA 1c ) change from baseline to week 40 (for the 12-mg once daily and 36-mg once daily dosages of orforglipron). Key secondary outcomes were mean HbA 1c change from baseline (for the 3-mg once daily dosage of orforglipron), proportion of participants achieving HbA 1c targets of lower than 7.0% and 6.5% or lower, and mean body weight change and percentage change from baseline to week 40.

Results

Among 546 randomized participants (median age, 61.0 [IQR, 26-95] years; 52.9% male; median duration of type 2 diabetes, 14.6 [IQR, 0.1-40.7] years; mean HbA 1c , 8.50% [SD, 0.95%]; mean body mass index, 30.8 [SD, 6.1]), 507 (92.9%) completed the trial. At week 40, the mean changes from baseline in HbA 1c were −1.58%, −1.88%, and −1.82% with orforglipron, 3 mg, 12 mg, and 36 mg once daily, respectively, vs −0.79% with placebo. Each dosage of orforglipron was superior to placebo (estimated treatment differences: 3 mg once daily, −0.78% [95% CI, −1.02% to −0.55%]; 12 mg once daily, −1.08% [95% CI, −1.33% to −0.83%]; 36 mg once daily, −1.03% [95% CI, −1.28% to −0.77%]; P < .001 for all). All key secondary outcomes demonstrated statistically significant differences in favor of orforglipron compared with placebo. Mean percentage body weight change from baseline was −2.6%, −4.8%, and −5.4% with orforglipron, 3 mg once daily, 12 mg once daily, and 36 mg once daily, respectively, vs 0.2% with placebo. The most frequent adverse events with orforglipron were gastrointestinal (mild to moderate). Orforglipron did not increase the risk of clinically significant hypoglycemia vs placebo. Conclusions and Relevance In participants with type 2 diabetes inadequately controlled by insulin glargine, addition of oral orforglipron significantly improved glycemic control and body weight, without increasing hypoglycemia risk, compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT06109311

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulin GlargineAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationGlycated HemoglobinHypoglycemiaMetforminFluorine CompoundsOxadiazolesAdministration, OralBody WeightGlycemic ControlTreatment Outcome

Substanzen

Blood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin GlargineMetforminorforglipronFluorine CompoundsOxadiazoles

Autor:innen und Institutionen

  • Department of Regenerative and Precision Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
  • St Luke's Endocrinology, Boise, Idaho.
  • Eli Lilly and Company, Indianapolis, Indiana.
  • Tokyo-Eki Centre-Building Clinic, Tokyo, Japan.

Zitieren

APA

Giorgino, F., D'Souza, S., Ludwig, L., Kiyosue, A., Ibriga, H., Rha, H., Denning, M., Wu, W. S., Fernández Landó, L., & Tobian, J. (2026). Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes. JAMA. https://doi.org/10.1001/jama.2026.9512

Vancouver

Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes. JAMA. 2026. doi:10.1001/jama.2026.9512

BibTeX
@article{Giorgino2026,
  author = {Giorgino, Francesco and D'Souza, Sherwin and Ludwig, Lisa and Kiyosue, Arihiro and Ibriga, Hilda and Rha, Hyungmin and Denning, Max and Wu, Wen-Shuo and Fernández Landó, Laura and Tobian, Janet},
  title = {Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.9512}
}
Kostenlos starten →